Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding Upstaza™ (eladocagene exuparvovec). This marks the first gene therapy administered directly into the brain, aimed at treating aromatic L-amino acid decarboxylase (AADC) deficiency. If approved by the European Commission, Upstaza would be the first disease-modifying treatment for AADC deficiency, significantly impacting motor and cognitive functions in patients. The expected ratification is within two months, covering all EU states and some additional countries.
PTC Therapeutics reported total revenues of $149 million for Q1 2022, marking a 26% year-over-year growth. The company highlighted strong performance in its Duchenne muscular dystrophy drugs, specifically $128 million in product revenue from Translarna™ and Emflaza®. PTC initiated the PIVOT-HD Phase 2 trial for PTC518 targeting Huntington's disease, with a CHMP opinion on AADC gene therapy anticipated in May. Despite a net loss of $126.7 million, PTC reaffirmed its 2022 revenue guidance of $700-$750 million.
PTC Therapeutics (NASDAQ: PTCT) announced its participation in two investor conferences. The company will give a presentation at the Bank of America Securities 2002 Healthcare Conference on May 10 at 5:20 p.m. PT and at the 2022 RBC Capital Markets Global Healthcare Conference on May 18 at 2:05 p.m. ET. Both presentations will be available via live webcast on the company's website, with an archive accessible for 30 days post-event. PTC focuses on developing medicines for rare disorders, emphasizing its commitment to patients' unmet medical needs.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on May 3, 2022, at 4:30 p.m. ET to discuss its first quarter 2022 financial results and provide a business update. Investors can join the call by dialing (877) 303-9216 in the U.S. or (973) 935-8152 outside the U.S. A live webcast will be available on the company's investor website. PTC is focused on developing medicines for rare disorders and aims to maximize value for patients and stakeholders.
PTC Therapeutics (NASDAQ:PTCT) announced the completion of Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment, PTC-AADC, aimed at AADC deficiency. The Committee for Advanced Therapies (CAT) will present a draft opinion to the Committee for Medicinal Products for Human Use (CHMP) in May 2022. If approved, PTC-AADC would be the first gene therapy infused directly into the brain, promising substantial benefits for patients suffering from this severe genetic disorder. Current treatment options are limited, making this potential approval significant.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has approved non-statutory stock options to purchase 86,130 shares and 33,125 restricted stock units (RSUs) for 96 new employees, as per the NASDAQ inducement grant exception. All stock options have an exercise price of $42.85, the closing price on April 8, 2022, and vest over four years with specific conditions. The RSUs also vest over four years. This decision was made by PTC's Compensation Committee in alignment with NASDAQ Listing Rule 5635(c)(4).
PTC Therapeutics (NASDAQ: PTCT) has initiated the PIVOT-HD Phase 2 clinical trial to evaluate PTC518 for Huntington's disease, a condition lacking current treatments targeting its underlying cause. This global trial will start in the U.S. and is divided into two phases: a 12-week placebo-controlled phase focusing on pharmacology and a 9-month phase assessing biomarker effects. Previous Phase 1 results indicated a dose-dependent lowering of huntingtin protein, which is critical for disease management.
PTC Therapeutics (NASDAQ: PTCT) announced the presentation of three posters on EMFLAZA™ (deflazacort) for Duchenne muscular dystrophy (DMD) at the MDA Clinical & Scientific Conference from March 13-16, 2022, in Nashville, TN. This marks the first presentation of data regarding steroid treatment outcomes in non-ambulatory DMD patients, supporting deflazacort's advantages over prednisone. Key presentations include associations between both steroid treatments and disease progression markers and milestones. A hybrid industry forum on corticosteroid treatment is set for March 15.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in two upcoming investor conferences. Management will present at the Cowen Virtual 42nd Annual Health Care Conference on March 7, 2022, at 1:30 p.m. ET, and at the Barclays Global Healthcare Conference on March 17, 2022, at 8 a.m. ET. Both presentations will be available via live webcast on the company’s website, where they will also be archived for 30 days post-event. PTC is committed to developing innovative medicines for rare disorders.
PTC Therapeutics (NASDAQ: PTCT) reported significant advancements in their pipeline and financial performance for Q4 and full-year 2021. Total revenues reached $538.6 million, up from $380.8 million in 2020, with DMD product revenues surpassing $400 million. Key milestones include a $25 million royalty from Evrysdi, marking it as the leading SMA therapy in the U.S. However, the company faced a net loss of $523.9 million in 2021 and expects total revenues of $700-$750 million in 2022, indicating strong growth alongside ongoing R&D investments.